Skip to main content
OpenTrials
Completed

NCT Number: NCT01941459

Comparison of Blood Cardioplegia and Custodiol

Thru the last 20 years it has been a discussion witch solution that gives the best myocardial protection during cardiac arrest by heart operations.

* It has been a tendency that a blood based cardioplegia gives a better protection bye long ischemic times but it has not been possible too conclude in this matter. * The investigators have two groups of cardioplegia, the blood based and, the crystalloid based cardioplegia. * It has been done a lot of studies to see what kind of cardioplegia that gives the best myocardial protection. Different temperature, different amount and content, retrograde or antegrade or both, contentiously and further on have been tested without a clear conclusion. * The investigators decided to make a study with a cohort of patients as homogenous as possible with a cross clamp time around 70 min. * Adult patients' with a severe aortic stenoses without any other significant heart disease was included in our prospective randomised study. * Patients with additional significant coronary artery disease (≥ 50% stenoses) were excluded from the study. * The investigators used the well known biomarkers CK-MB and troponin-T too evaluate the myocardial damage.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

thoraxkirurgisk avd, UUS

Oslo, Norway

About this study

Objective: Myocardial protection during a cardiac arrest is mostly managed with cardioplegia. To day we normally used a blood or crystalloid based solutions. It has been published a lot of papers comparing the too groups with different results. To our knowledge no prospective, randomized study has compared modified St Thomas based Blood and Crystalloid cardioplegia on the acknowledged markers (CK-MB, troponin-T) of myocardial damage during aortic valve replacement on patients without additional significant coronary artery disease.

Methods: 100 patients with aorta stenoses undergoing aortic valve replacement without significant coronary artery stenoses or other significant concomitant heart valve disease were included in the study. They were given antegrade cold blood or cold crystalloid cardioplegia delivered through the coronary Ostia every 20 min throughout the period of aortic cross-clamp. CK-MB and troponin-T were compared between the two groups.

Published 2010 in the journal of thoracic and cardiovascular surgery.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

The study protocol was approved by the local ethical committees. Eligible for operation were:

Inclution Criteria

  • patients with mitral regurgitation equal to or larger than grade 3 out of 4.
  • Ablation for atrial fibrillation was the only concomitant procedure that was allowed in addition to mitral valve surgery and these patients were block-randomized to ensure equally many patients with ablation in the two groups of cardioplegia.

Exclusion criteria

  • Patients with any other concomitant heart valve disease or coronary artery stenoses (≥ 50%) were excluded from the study.
  • Age below 18
  • Pregnant

Treatment and study plan

Primary outcomes

  1. CK-MB ,troponin-T

    Time frame: 72 hours

Sponsors and collaborators

Lead sponsor

Ullevaal University Hospital

Other

Registry information

Official study title

Comparison of Blood Cardioplegia and Custodiol on Patients Operated for Significant Mitral Valve Innsufisiens. An Prospective, Randomized Two-center Study.

Important dates

Study start
2007
Primary completion
2009
Study completion
2010
First posted
Sep 13, 2013
Registry last updated
Sep 13, 2013

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.